GalR1 and GalR2 represent unique pharmacological targets for treatment of seizures and epilepsy. A novel series of 2, 4, 6-triaminopyrimidine derivatives were synthesized and found to have sub-micromolar affinity for GalR2. Optimization of a series of 2, 4, 6- triaminopyrimidines led to the discovery of several analogs with IC50 values ranging from 0.3 to 1μM.